Latest
Psychedelic Drugs Nearer to Medical Approval in Europe, but Hurdles Remain

Psychedelic drugs may soon become a reality for European patients struggling with complex mental health issues, as research into their therapeutic potential gains momentum. Despite decades of stigma, studies on psychedelics like LSD, psilocybin (from magic mushrooms), and MDMA (ecstasy) are picking up speed, although obstacles remain before these treatments are fully integrated into medical practice.
For years, psychedelics were primarily known as recreational drugs associated with hallucinogenic effects. Research into their potential medical benefits largely stopped in the 1970s across Europe and North America. However, today, these substances are once again being explored for their ability to address mental health conditions such as depression, addiction, and post-traumatic stress disorder (PTSD).
Countries like Switzerland and Australia have already begun offering limited access to psychedelic treatments. While the European Union (EU) has yet to approve psychedelic therapies, around 20 studies are underway to assess psilocybin and MDMA for a variety of psychiatric disorders.
A key figure in the field, Ulf Bremberg, founder of HumanKindLabs and researcher at Uppsala University, said, “This is such a different way to treat psychiatric disorders.” Most psychedelic treatments pair the drug with therapy, allowing patients to process their experiences in a controlled setting. These approaches offer a new perspective on trauma and emotional pain.
The Promise and Skepticism of Psychedelics
Supporters of psychedelic therapy argue that it could revolutionize mental health treatment in a way not seen since the introduction of antidepressants in the 1970s. Early research suggests psychedelics may help treat depression, obsessive-compulsive disorder (OCD), and even chronic pain. However, critics caution that the research is still in its infancy, with many small-scale studies hard to replicate.
Henrik Jungaberle, head of the Berlin-based MIND Foundation, pointed out that the hype surrounding psychedelics has faded as more comprehensive studies are conducted. “We are post-hype,” he said, emphasizing the need for robust research that includes diverse populations.
In the UK, Rayyan Zafar, a neuropsychopharmacologist at Imperial College London, is leading a study on psilocybin for gambling addiction. His research explores how psychedelics may rewire the brain’s reward system, offering a potential breakthrough for those struggling with addictive behaviors.
Future of Psychedelic Therapies in Europe
UK-based Compass Pathways is currently leading a major study across 10 European countries to test psilocybin for treatment-resistant depression. The results are promising, with patients showing significant improvements after just one dose. A phase 3 trial, the final step before seeking regulatory approval, is now underway.
Despite the excitement, setbacks in the US, including the recent rejection of an MDMA-assisted therapy application, have caused some delays in the progress of psychedelic treatments. Nevertheless, European researchers remain optimistic that these therapies will eventually gain approval, though challenges like insurance coverage and doctor buy-in remain.
With large-scale trials and growing interest in the field, Europe may soon see psychedelic drugs prescribed for mental health treatment, offering new hope for patients with difficult-to-treat conditions.
Latest
Flash Floods Devastate Thai Elephant Sanctuary, Killing Two Elephants and Forcing Evacuations
Latest
Severe Drought Causes Record Low Water Levels in Brazil’s Negro River
Latest
Oxford Scientists Develop First Ovarian Cancer Vaccine in Groundbreaking Research
-
Business10 months ago
Saudi Arabia’s Model for Sustainable Aviation Practices
-
Business10 months ago
Recent Developments in Small Business Taxes
-
Politics10 months ago
Who was Ebrahim Raisi and his status in Iranian Politics?
-
Business8 months ago
Carrectly: Revolutionizing Car Care in Chicago
-
Business8 months ago
Saudi Arabia: Foreign Direct Investment Rises by 5.6% in Q1
-
Technology10 months ago
Comparing Apple Vision Pro and Meta Quest 3
-
Politics10 months ago
Indonesia and Malaysia Call for Israel’s Compliance with ICJ Ruling on Gaza Offensive
-
Technology10 months ago
Recent Developments in AI Ethics in America